Erasca Secures New Patent for ERAS-4001 Until 2043
Erasca announced that the U.S. Patent and Trademark Office has issued Patent No. 12,552,813, titled "Heterocyclic Substituted Pyrimidopyran Compound And Use Thereof." The patent claims protect the composition of matter for Erasca's potentially first-in-class pan-KRAS inhibitor ERAS-4001 and related compositions until June 2043, which may be subject to patent term adjustments or extensions affording even later protection. "This newly issued U.S. patent strengthens our ERAS-4001 program, builds on the momentum of our RAS franchise which includes our potential first-in-class pan-KRAS inhibitor ERAS-4001 and our potential best-in-class pan-RAS molecular glue ERAS-0015, and advances our diversified intellectual property strategy in RAS-driven cancers," said Jonathan E. Lim, M.D., Erasca's chairman, CEO, and co-founder. "With patent protection extending through at least 2043, the ERAS-4001 program is supported by a robust, long-term IP foundation, with additional patents pending. As both RAS-targeting molecules continue to advance rapidly in the clinic, we look forward to reporting Phase 1 data for ERAS-0015 in the first half of the year and for ERAS-4001 in the second half of the year."
